IL1RAP is an immunotherapeutic target for normal karyotype triple-mutated acute myeloid leukemia.

ABSTRACT:

Background

Surface antigens of potential clinical significance remain under-characterized in AML. The European Leukemia Network classifies normal karyotype AML (NK-AML) mutated for NPM1 (NPM1c) as a distinct entity associated with favorable outcomes if not associated with FLT3-ITD mutation. A subset of NPM1c NK-AML shows additional mutations in 2 genes: FLT3 (FLT3-ITD) and DNMT3 A. These leukemias, also referred to as NK triple mutated AML (NKt-AML), are particularly difficult to eradicate with current treatment options. Therefore, novel therapies are necessary that use proteins specifically expressed at the surface.

Methods

In order to identify surface antigens for immunotherapy in NKt-AML, an extensive multi-omic analysis was conducted on primary AML samples. Surface prote

SUBMITTER: Metois A 

PROVIDER: S-EPMC11995633 | biostudies-literature | 2025 Apr

REPOSITORIES: biostudies-literature